Abstract

Objectives: Intracranial alveolar echinococcosis (IAE), a zoonotic disease, is a critical health problem in the Tibetan region. We aimed to describe the clinical and radiological characteristics and outcomes among patients with IAE.Methods: We screened patients diagnosed with IAE between March 2015 and May 2019 at the Ganzi Tibetan Autonomous Prefecture People's Hospital. Detailed demographics, clinical characteristics, neuroimaging features, and outcomes were recorded.Results: A total of 21 patients with an average age of 44.1 ± 12.7 years were included. Thirteen (61.9%) patients were male. The most common chief neurological complaint was headache (n = 17, 81.0%), followed by dizziness, seizure, visual disturbances, hemiparesis, disturbed consciousness, and dysphasia. All the patients had coexisting liver localizations. The typical neuroimaging features of IAE on cerebral magnetic resonance imaging scans showed obvious low-signal shadow with multiple small vesicles inside the lesions on T2-weighted images and FLAIR images. The pathological HE staining demonstrates vesicular lesions with several internal sacs. For hepatic alveolar echinococcosis (AE), the hepatic portal was invaded in six (28.6%) patients, and the portal vein (n = 5, 23.8%) was the mostly commonly involved vessel. As for treatment, 11 patients (52.4%) had poor compliance with albendazole. The duration of patients taken albendazole ranged from 2 months to 3 years. Cerebral AE surgery was performed in 11 patients, five of them underwent partial resection of AE lesions, and six patients received total resection. One patient with primary IAE underwent radical surgery. Ten patients (47.6%) died during the follow-up for a mean of 21.7 ± 11.9 (3–46) months. In total, 28.9% of the patients died within 5 years, and 71.6% died within 10 years. The median interval between the date of diagnosis as AE and death was 84 (19–144) months.Conclusion: Despite substantial advances in diagnostic and therapeutic methods, the treatment of IAE remains difficult and results in unsatisfactory outcomes. The major critical issue is surgical treatment of IAE although the disease is disseminated. Besides, lifelong albendazole would be indicated, but most patients had poor medication compliance. It is important to educate patients about the necessity of medical treatment.

Highlights

  • Echinococcus, which causes severe echinococcosis or hydatid disease, is a zoonotic tapeworm found in several parts of the world [1]

  • One hundred and six patients clinically diagnosed with Intracranial alveolar echinococcosis (IAE) were collected from March 2015 to May 2019, of which 99 were followed-up with a mean duration of 23.3 ± 13.74 [2– 54] months

  • After exclusion of 85 possible cases of IAE without pathological information, a total of 21 patients diagnosed with IAE were enrolled in this study and received follow-up for a mean duration of 21.7 ± 11.9 [3–46] months

Read more

Summary

Introduction

Echinococcus, which causes severe echinococcosis or hydatid disease, is a zoonotic tapeworm found in several parts of the world [1]. Cystic echinococcosis (CE) and alveolar echinococcosis (AE) are caused by Echinococcus granulosus and Echinococcus multilocularis, respectively [2]. Intracranial alveolar echinococcosis (IAE) is rare, accounting for only 1% of patients with hepatic AE [7]. Studies on IAE are rare and usually published as case reports [11, 13,14,15]. The clinical features and outcomes of the condition are not well-understood in the absence of a systematic study. In this retrospective study with follow-up, we aimed to gain further understanding of IAE regarding clinical features, neuroimaging, and outcomes

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call